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and invasion (18) , an effect that is enhanced when cysteine cathepsin inhibitors are combined with chemotherapy (19) . Taken together, these data indicate that cysteine cathepsins have important roles in metastasis. Since bone is the most common site of distant metastasis in breast cancer patients, determining the roles of cysteine cathepsins in bone metastasis is crucial.
Our previous studies support a role for cysteine cathepsins in bone metastasis (20) . Using our unique 4T1.2 syngeneic model of spontaneous bone metastasis (21) , we identified the endogenous cysteine cathepsin inhibitor stefin A as a metastasis suppressor. Tumor cell stefin A significantly reduced pulmonary and bone metastasis in the murine model and was an independent predictor of good prognosis in a cohort of 142 breast cancer patients (20) . Of the cysteine cathepsins, cathepsin B was co-expressed with stefin A in primary tumors and metastases, suggesting that stefin A suppressed metastasis via inhibition of cathepsin B. This was supportive of previous studies that demonstrate that a shift in equilibrium between cathepsin B and its endogenous inhibitor stefin A predicts poor survival outcomes (22, 23) .
In this study, we utilized our 4T1.2 model to demonstrate a critical function of cathepsin B in breast cancer metastasis to bone. Molecular suppression and selective therapeutic inhibition of cathepsin B significantly reduces pulmonary and bone metastasis. This study provides evidence that cathepsin B is a potential therapeutic target for treatment of breast cancer patients with metastatic disease. Author Manuscript Published OnlineFirst on January 19, 2012; DOI:10.1158/0008-5472. CAN-11-2759 Cathepsin B inhibition reduces bone metastasis 5
Methods:
Immunohistochemistry (IHC). All tissues were fixed in 10% neutral buffered formalin for 24 hours, bones decalcified in 20% EDTA, pH 8.0 and embedded in paraffin. Archived human material was utilized where previous informed consent was obtained from all patients. Citrate buffer (10mM, pH 6.0) high temperature and pressure antigen retrieval was required for human tissues and IHC was then carried out on tissue sections as described previously (20) .
Cell maintenance. The 4T1.2 lines (21) were derived in our laboratory from the parental mouse 4T1 mammary tumor cell line. The 4T1 cell line was derived by Fred Miller that, along with a series of other lines, was originally derived from a spontaneous mammary tumor in Balb/c mice. Cells were maintained in alpha-modified eagle medium (α-MEM) supplemented with 5% fetal bovine serum (FBS, JRH Biosciences, KA, USA) and cultured at 37°C in an atmosphere of 5% CO 2 for no more than 4 weeks. Immunocytochemistry. 4T1.2, 4T1.2 BV and CTSB kd cells were grown on uncoated glass coverslips for 24 hours, fixed in 3.7% cold paraformaldehyde and then blocked in PBS containing 2 mg/ml BSA.
Cells were then incubated overnight at 4°C with primary antibody, rabbit anti-human cathepsin B (24).
Cathepsin B expression was detected with FITC Alexa Fluor 488 donkey anti-rabbit secondary antibody (Invitrogen, CA, USA) and imaged on a Zeiss LSM 510 META confocal microscope.
Live cell proteolysis assay. Proteolysis was measured according to previously published procedures (26, 27) . Briefly, glass coverslips were coated with 50 μl of 25 mg/ml quenched fluorescent substrate DQ-collagen IV (Invitrogen, CA, USA) mixed with reconstituted basement membrane (rBM) Cultrex (Trevigen, MD, USA). For collagen I, plastic coverslips were coated with 100 μl of 25 mg/ml DQcollagen I (Invitrogen, CA, USA) mixed with collagen I (Advanced BioMatrix, CA, USA). The ratio of quenched fluorescent components to non-fluorescent components was 1:40 for all experiments. Cells were seeded at a density of 5000 cells per coverslip and cultured in serum-containing medium for 48 hours. Activity based probe GB123 (1 μM) was added to the media 16-18 hours prior to imaging.
Fluorescence was then observed by confocal microscopy on a Zeiss LSM 510 using a 40x water immersion lens. Cell lysates labeled with GB123 were separated by SDS-PAGE and visualized by scanning with a typhoon flatbed laser scanner (excitation/emission 633/680nm). For inhibitor studies, the highly selective cathepsin B inhibitor CA-074 was synthesized and purified in the Bogyo laboratory, CA, USA and used at 20 μM (in DMSO vehicle) and replenished after 24 hours. The fluorescent GB123 probe was produced as described previously (28) . 29 and until signs of metastasis were evident in either group, at which point all mice were culled and assessed for metastatic burden. Any mice with primary tumor re-growth were excluded from the study.
Mouse studies were conducted only after approval by the Peter MacCallum Ethics Review Board.
Non-invasive imaging of 4T1.2 tumor burden mice. 4T1.2 cells were injected into the 4th mammary fat pad of 6 week old Balb/c mice followed 3 days later by daily intra-peritoneal injections of CA-074 (50mg/kg) or vehicle (5% DMSO/Saline.) Probes (25 nmol GB123 or 2 nmol osteosense750, VisEn
Imaging, Inc.) were administered through the tail vain in a solution of 67% DMSO, 33% PBS in 100μl
final volume, 24 hours prior to imaging. Mice were then anesthetized with 3% isoflurane, and tomographic images taken using the FMT2500 imaging system, using the 680nm or 750nm channels.
All animal experiments were approved by the Stanford Administrative Panel on Animal Care. The decrease in lung metastatic burden was confirmed by histology ( Figure 3D ). Of particular interest to this study, bone (spine) metastasis was also reduced dramatically in the CTSB kd group compared to 4T1.2 ( Figure 3E However, analysis of metastasis revealed a significant difference between these compounds. Treatment with the broad spectrum JPM-OEt inhibitor did not significantly reduce metastasis to lung or bone when compared to vehicle ( Figure 4B and 4C) . In contrast, CA-074 treatment significantly decreased Figure 4E , p<0.05) and bone ( Figure 4F, p<0.05 ). The effect of the inhibitors in vivo was further confirmed by histopathological analysis. Visible lung and spine metastatic nodules were observed in vehicle and JPM-OEt treatment groups, whereas tumors were undetectable in the CA-074 group (Figure 4H, 4I) . Importantly, measurement of cysteine cathepsin B and L activity in primary tumor tissue lysates derived from mice treated with JPM-OEt and CA-074 revealed that both inhibitors reduced tumor cathepsin B activity significantly ( Figure 4G, p<0.005 ), yet CA-074 was more effective.
In contrast, only JPM-OEt inhibited cathepsin L activity ( Figure 4G, p<0.05) . Hence, the reduced efficacy of JPM-OEt could be due to the inhibition of other cysteine cathepsins that may have antitumorigenic functions (33) and/or due to a slightly reduced ability to suppress cathepsin B activity.
The CA-074 treatment studies were conducted from day 3 until metastasis was evident. This did not specifically allow assessment of the role of cathepsin B in the later steps of metastasis, preventing metastatic outgrowth once tumor cells had already lodged in distant tissues. We therefore performed a repeat CA-074 treatment experiment aimed at recapitulating a late-treatment setting. Primary tumors were removed and treatment began at day 20, a time when micrometastases can be detected in lung and bone. Analysis of metastatic burden revealed that there was a significant decrease in lung and overall bone metastases in this setting ( Figure 5 ), revealing a role for cathespin B in late stages of metastatic spread. 
Non-invasive in vivo

Discussion:
Bone metastases occur in a high proportion of breast cancer patients with metastatic disease and are associated with severe morbidity and eventual mortality when visceral organs become involved.
Dissecting the molecular mechanisms involved in tumor cell survival and outgrowth in bone is essential for the development of targeted therapies to reduce patient mortality. Here we report that tumor-derived cathepsin B is a key contributor to bone metastasis. Our data demonstrate for the first time that selective inhibition of cathepsin B using small molecule inhibitors significantly reduces metastasis and has therapeutic potential.
There are a number of critical steps required for growth of tumors in bone. This includes collaboration between the tumor cells themselves and the bone stroma for stimulating angiogenesis, invasion through the bone matrix and growth beyond the micrometastatic stage. Cathepsin B upregulation has been documented in several human cancers, including breast, prostate and melanoma (15, 34, 35) . Our data demonstrate that cathepsin B has critical tumor-specific functions in breast cancer metastasis that are completely independent from primary tumor growth. We show that tumor cells themselves can directly 
macrometastases requires multiple steps including invasion through secondary tissues, preventing ECM degradation by cathepsin B inhibition is likely to reduce metastatic burden.
Cathepsin B has also been implicated in stromal cell-associated pro-tumorigenic functions. In breast cancer, this has been demonstrated using the MMTV-PyMT model where host-derived cathepsin B promotes lung metastasis (39) . The expression of cathepsin B predominantly in tumor-infiltrating macrophages indicated that macrophage derived cathepsin B contributed to metastasis. The expression of cathepsin B in tumor-associated endothelial cells and macrophages has been associated with tumor progression via promotion of angiogenesis (17, 18) . Cathepsin B has also been reported to be expressed in stromal fibroblasts and macrophages in colon and prostate cancers (40, 41) . Taken CAN-11-2759 been documented to suppress the formation and growth of breast cancer osteolytic lesions in experimental models of metastasis.
The therapeutic benefit of CA-074 treatment in the 4T1.2 model was in contrast to the broad spectrum inhibitor JPM-OEt, which did not decrease lung or spine metastases. In agreement with our studies, treatment of polyoma middle T oncogene-induced mammary carcinomas with JPM-OEt did not alter tumor weights and lung metastasis (33) . Together, these studies reveal the importance of using specific targeted therapies in vivo. JPM-OEt targets several cysteine cathepsins, some of which could actually have tumor suppressive functions. For example, cathepsin L activity is decreased in highly metastatic 4T1.2 tumors compared to weakly or non-metastatic tumors (20) suggesting inhibitory effects of this protease on tumor progression, as has been suggested before in skin tumorigenesis (44) . The importance of using specific protease inhibitors is clear from early clinical trials using MMP inhibitors where inhibition of certain MMPs actually has deleterious effects in patients (45, 46) . These studies highlight the significant effort needed to determine which specific proteases contribute to advanced disease progression before potential drugs can be tested in the clinic.
Current treatments available for patients with bone metastasis are aimed primarily at reducing the morbidity associated with bone lysis, a hallmark of breast cancer bone disease. One target of such treatments is cathepsin K. Cathepsin K is expressed predominantly in osteoclasts where it is secreted and has a key role in bone proteolysis, including degradation of collagen I, osteonectin and osteopontin (47) . The potential role of cathepsin K in osteolytic bone tumors is evident from its expression in tumor associated osteoclasts (48) , in breast and prostate metastases in bone and in giant cell tumor of bone (49) . Cathepsin K inhibitors block bone resorption (50) 
